SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cambridge Antibody Technology Group
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (254)4/18/2002 6:41:58 PM
From: nigel bates  Read Replies (1) of 625
 
Certainly as informed as I am. <g>

The $1bn figure wasn't mine, FWIW. I saw the estimate in a couple of places. I'll try to hunt them down, & post them.

These were my notes (!) on anti-IL-12 from the H&Q presentation - J695 (Abbott) - mid P11 in RA & Crohns (?). Can't say much as it's pharma.
From memory, there was definitely a strong hint they were actively pursuing indications other than than RA, but it's clearly one of those no publicity deals... $10m is probably right for now, but you never know.

nig
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News